Sangamo Therapeutics

FDA Approval In 2026 Will Extend Fabry Gene Therapy Prospects

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

01 Apr 25

Updated

27 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-77.3%

7D

-5.1%

Loading

1Y

-77.3%

7D

-5.1%

You can edit this narrative until Nov 28 5:10 AM. Then, changes will post as Updates.

Author's Valuation

US$3.2586.5% undervalued

AnalystConsensusTarget Fair Value

Shared on 27 Nov 25

SGMO: FDA Accelerated Pathway Will Extend Bullish Momentum Into 2026

Analysts have lowered Sangamo Therapeutics’ price target from $5 to $1, citing uncertainty around future partnership deals. This is despite recent regulatory updates and an extended cash runway.

Shared on 08 Nov 25

Fair value Decreased 21%

SGMO: FDA Approval Path Will Drive Bullish Outlook Into 2026

Analysts have lowered their price target for Sangamo Therapeutics from $5 to $1. They cited a cautious outlook, pending greater clarity on a Fabry collaboration and updated guidance following the company's latest quarterly report.

Shared on 21 Sep 25

Fair value Increased 56%

The sharp increase in Sangamo Therapeutics' consensus analyst price target is primarily driven by a significantly higher future P/E expectation, indicating greater anticipated earnings growth or improved sentiment, with the fair value rising from $2.62 to $4.10. What's in the News CFO Prathyusha Duraibabu resigned, effective October 1, to join a private AI company; no disagreements cited in her departure.

Shared on 06 Sep 25

Fair value Decreased 36%

Sangamo Therapeutics' fair value has been revised downward, primarily reflecting meaningful declines in both its forward P/E multiple and net profit margin, resulting in a lower consensus price target of $2.62. What's in the News Sangamo presented detailed data from the registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), its investigational gene therapy for adults with Fabry disease, showing a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year in all patients followed at least 12 months.

Shared on 01 May 25

Fair value Decreased 20%

Shared on 24 Apr 25

Fair value Decreased 3.58%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.

Shared on 17 Apr 25

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 80.4x to 94.6x.

Shared on 09 Apr 25

Fair value Increased 30%

AnalystConsensusTarget has decreased revenue growth from 44.4% to 23.0%, increased profit margin from 10.5% to 19.3%, increased future PE multiple from 71.3x to 80.4x and decreased shares outstanding growth rate from 0.1% to 0.1%.

AnalystConsensusTarget Fair Value

US$3.25

86.5% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

46.06%

Biotech revenue growth rate

8.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.30%

Calculation

US$48.92m

Earnings '28

x

60.75x

PE Ratio '28

=

US$2.97b

Market Cap '28

US$2.97b

Market Cap '28

/

739.28m

No. shares '28

=

US$4.02

Share Price '28

US$4.02 Share Price '28

Discounted to 2025 @ 7.34% p.a.

=

US$3.25

Fair Value '25